Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 49 results:
Συντάκτης [ Τίτλος![(Asc)](https://www.med.auth.gr/sites/all/modules/biblio/misc/arrow-asc.png)
Φίλτρα: Συντάκτης is Makras, Polyzois [Clear All Filters]
Ιrisin levels in postmenopausal women with an incident hip fracture..
Endocrine. 73(3), 719-722.
(2021).
(2019).
(2020).
THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis..
Eur J Endocrinol. 179(1), R31-R45.
(2018). Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis..
Hormones (Athens). 10(3), 174-95.
(2011).
(2023).
Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis..
J Clin Endocrinol Metab. 97(4), E618-21.
(2012). Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?.
Mol Ther. 20(1), 6-7.
(2012). The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass..
Clin Endocrinol (Oxf). 77(6), 816-22.
(2012).
(2023).
(2020).
Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations..
Maturitas. 147, 19-25.
(2021). Periostin and sclerostin levels in juvenile Paget's disease..
Clin Cases Miner Bone Metab. 14(2), 269-271.
(2017). Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis..
Clin Endocrinol (Oxf). 79(4), 499-503.
(2013).
(2012). Off-label uses of denosumab in metabolic bone diseases..
Bone. 129, 115048.
(2019). Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment..
Hormones (Athens). 17(4), 573-579.
(2018). No effect of rosuvastatin in the zoledronate-induced acute-phase response..
Calcif Tissue Int. 88(5), 402-8.
(2011). Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?.
Calcif Tissue Int. 103(1), 107-108.
(2018). Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity..
Metabolism. 71, 198-201.
(2017). Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab..
Ther Clin Risk Manag. 8, 295-306.
(2012).
(2023).
(2016). Irisin in metabolic diseases..
Endocrine. 59(2), 260-274.
(2018). Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?.
Metabolism. 93, 100-102.
(2019).